

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Peijia Medical Limited**

**沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

## **VOLUNTARY ANNOUNCEMENT**

### **ReachTactile™ ROBOTIC-ASSISTED TAVR SYSTEM SUCCESSFULLY COMPLETED THE FIRST PATIENT TREATMENT**

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on April 2, 2025, the Company completed the first patient treatment of the first-in-man clinical trial of ReachTactile™ robotic-assisted transcatheter aortic valve replacement (“**TAVR**”) system. The procedure was performed by Professor Yan Wang and his team in Xiamen Cardiovascular Hospital of Xiamen University, utilizing the ReachTactile™ robotic-assisted TAVR system to implant a TaurusElite® transcatheter aortic valve in a patient with severe aortic stenosis.

ReachTactile™, the Company’s internally developed robotic-assisted TAVR system, offers an innovative, cost-effective solution for TAVR therapy. The mobile, modular design fits conventional catheter rooms, allowing a single cardiologist to operate multiple devices with sub-millimeter precision. A force-sensing mechanism provides real-time tactile feedback, aiding navigation in complex vascular conditions. The Master Unit-Slave Unit architecture allows cardiologists to reduce radiation exposure and other occupational diseases. Meanwhile, remote control capabilities via ethernet enable long-distance operations and training.

**THE COMPANY MAY NOT BE ABLE TO ULTIMATELY MARKET THE ReachTactile™ ROBOTIC-ASSISTED TAVR SYSTEM SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.**

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Hong Kong, April 6, 2025

*As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN, Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. WaiMing YIP and Mr. Huacheng WEI as independent non-executive Directors.*